USA - NYSE:HNGE - US4333131039 - Common Stock
The current stock price of HNGE is 41.75 USD. In the past month the price decreased by -17.72%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.57 | 100.50B | ||
| CI | THE CIGNA GROUP | 9.54 | 72.31B | ||
| LH | LABCORP HOLDINGS INC | 16.93 | 22.26B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.22 | 20.98B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 106.96 | 19.33B | ||
| GH | GUARDANT HEALTH INC | N/A | 11.74B | ||
| DVA | DAVITA INC | 13.33 | 8.80B | ||
| HIMS | HIMS & HERS HEALTH INC | 66.76 | 8.15B | ||
| CHE | CHEMED CORP | 20.27 | 6.50B | ||
| RDNT | RADNET INC | 193.32 | 5.65B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 31.13 | 5.62B | ||
| OPCH | OPTION CARE HEALTH INC | 19.35 | 4.68B |
Hinge Health, Inc. is a digital healthcare company, which engages in software for joint and muscle health care. The company is headquartered in San Francisco, California and currently employs 1,514 full-time employees. The company went IPO on 2025-05-22. The firm has designed its TrueMotion platform to address a spectrum of musculoskeletal (MSK) care from acute injury to chronic pain, to post-surgical rehabilitation. Members receive personalized and automated MSK care through its AI-powered motion tracking technology. The company offers electrical nerve stimulation wearable device Enso, all designed and monitored by its AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Its platform offers a range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. Enso delivers electrical nerve stimulation designed to provide non-addictive and non-invasive pain relief.
HINGE HEALTH INC-A
455 Market Street, Suite 700
San Francisco CALIFORNIA US
Employees: 1514
Phone: 14156898429
Hinge Health, Inc. is a digital healthcare company, which engages in software for joint and muscle health care. The company is headquartered in San Francisco, California and currently employs 1,514 full-time employees. The company went IPO on 2025-05-22. The firm has designed its TrueMotion platform to address a spectrum of musculoskeletal (MSK) care from acute injury to chronic pain, to post-surgical rehabilitation. Members receive personalized and automated MSK care through its AI-powered motion tracking technology. The company offers electrical nerve stimulation wearable device Enso, all designed and monitored by its AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Its platform offers a range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. Enso delivers electrical nerve stimulation designed to provide non-addictive and non-invasive pain relief.
The current stock price of HNGE is 41.75 USD. The price decreased by -1.37% in the last trading session.
HNGE does not pay a dividend.
HNGE has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
21 analysts have analysed HNGE and the average price target is 64.99 USD. This implies a price increase of 55.66% is expected in the next year compared to the current price of 41.75.
HINGE HEALTH INC-A (HNGE) has a market capitalization of 3.27B USD. This makes HNGE a Mid Cap stock.
The outstanding short interest for HINGE HEALTH INC-A (HNGE) is 8.71% of its float.
ChartMill assigns a technical rating of 1 / 10 to HNGE.
ChartMill assigns a fundamental rating of 4 / 10 to HNGE. HNGE has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months HNGE reported a non-GAAP Earnings per Share(EPS) of -0.15. The EPS increased by 88.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1.72% | ||
| ROE | -3.19% | ||
| Debt/Equity | 0 |
21 analysts have analysed HNGE and the average price target is 64.99 USD. This implies a price increase of 55.66% is expected in the next year compared to the current price of 41.75.
For the next year, analysts expect an EPS growth of 488.89% and a revenue growth 43.83% for HNGE